Imugene Receives AU$5.87 Million R &D Tax Refund to Support Oncology Pipeline

Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, has received an AU$5,872,248 research and development (R&D) tax refund for the 2024 financial year, which includes AU$84,990 in interest. The refund was granted under the Australian Government’s R&D tax incentive, offering up to a 48.5% refundable offset for eligible activities.

This funding will help accelerate the clinical development of Imugene’s innovative immunotherapy pipeline. The company is advancing multiple programs, including its allogeneic CAR T therapy azer-cel for blood cancers, B-cell vaccine candidates, and the CF33 oncolytic virus therapy targeting solid tumours. Imugene continues to leverage its cutting-edge technology and expert international team to progress treatments aimed at improving cancer outcomes and transforming patient care.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com